our products
Contact phone

Piqray

Cancer Piqray (Generic) Generic drugs, marketed without brand names, contain the exact same active ingredients used in their brand-name counterparts, but cost significantly less. The drugs are required to meet US Food and Drug Administration (FDA) standards for safety, purity and effectiveness.
Piqray

Patients with HR-positive, HER2-negative breast cancer that has progressed or spread to other areas of the body, including postmenopausal women and men, are candidates for treatment with alpelisib (metastatic). You will only be prescribed alpelisib if your cancer carries a certain genetic marker (an abnormal "PIK3CA" gene). This gene will be checked for in you by your primary care physician.

BEST DEAL!

Save 20% with

Coupon "PKVCbYFj9G"

Piqray: A Breakthrough in Breast Cancer Treatment

Introduction

Breast cancer is a devastating disease that affects millions of women worldwide. While there have been significant advancements in treatment options, researchers are constantly striving to find new and improved therapies. In recent years, a revolutionary drug called Piqray has emerged as a game-changer in the field of breast cancer treatment. Piqray, also known as alpelisib, is a targeted therapy that has shown remarkable results in treating certain types of breast cancer. In this blog post, we will explore the mechanism of action of Piqray and its potential benefits for patients.

The Mechanism of Action of Piqray

Piqray belongs to a class of drugs called PI3K inhibitors. It works by specifically targeting and inhibiting an enzyme called phosphoinositide 3-kinase (PI3K), which plays a crucial role in the growth and survival of cancer cells. By blocking the activity of PI3K, Piqray helps to halt the signaling pathways that promote cancer cell growth and division. This targeted approach makes Piqray a highly effective treatment option for patients with hormone receptor-positive, HER2-negative breast cancer that carries a specific genetic mutation known as PIK3CA.

Benefits of Piqray for Breast Cancer Patients

Clinical trials have demonstrated the remarkable efficacy of Piqray in treating advanced breast cancer. In a landmark study, patients who received Piqray in combination with an aromatase inhibitor experienced a significant improvement in progression-free survival compared to those who received the placebo. This means that Piqray can effectively delay the progression of the disease, giving patients more time before their cancer worsens. Furthermore, Piqray has shown potential in reducing the size of tumors and preventing the spread of cancer to other parts of the body, thus increasing the chances of successful treatment and improved overall survival rates.

Conclusion

Piqray represents a major breakthrough in breast cancer treatment. Its targeted mechanism of action and impressive clinical results make it a promising option for patients with hormone receptor-positive, HER2-negative breast cancer that carries the PIK3CA mutation. However, it is important to note that Piqray is not suitable for all breast cancer patients and should be prescribed based on individual genetic profiles and medical history. As research continues to advance, we can hope for more innovative therapies like Piqray that bring us closer to a future where breast cancer is no longer a life-threatening disease.

Testimonials

high quality medications

Free discreet shipping

Secure online transactions

Money-back guarantee

Fast worldwide delivery

By staying on our site you automatically agree with the storage and processing of your personal data, in accordance with our Privacy Policy.